Physician profile
Stephen Aronoff
NPI 1538106844
$216,767.93
in general payments reported to CMS, 2019-2025
73 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $20K · 2021: $13K · 2022: $11K · 2023: $30K · 2024: $28K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $4,974 · Travel and Lodging: $1,802 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,110.25 |
| Food and Beverage | $4,973.61 |
| Travel and Lodging | $1,802.35 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $177,701.98 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $13,433.13 | 2019-2023 | Farxiga, Lokelma |
| Abbvie INC. | $7,972.11 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Tandem Diabetes Care, INC. | $7,350.00 | 2019-2021 | |
| Novo Nordisk INC | $1,357.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,186.66 | 2019-2025 | Baqsimi, Jardiance, Lyumjev |
| Kvk-Tech, INC. | $638.46 | 2019-2021 | |
| Insulet Corporation | $593.81 | 2019-2023 | Omnipod |
| Amarin Pharma, INC. | $449.40 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $427.05 | 2019-2023 | Strensiq |
| Eisai INC. | $319.20 | 2019-2022 | |
| Mannkind Corporation | $286.26 | 2019-2024 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.73 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $280.38 | 2019-2022 | |
| Dexcom, INC. | $260.33 | 2019-2025 | Dexcom G6 Transmitter |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $259.07 | 2020-2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $258.79 | 2020-2025 | Gvoke Hypopen |
| Radius Health, INC. | $258.08 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $218.40 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $195.17 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $181.62 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $170.22 | 2021-2025 | Unithroid |
| Intuity Medical INC | $167.60 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Idorsia Pharmaceuticals US INC | $157.87 | 2023-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $153.51 | 2020-2024 | Onzetra Xsail, Contrave |
| Ascendis Pharma Endocrinology INC | $140.31 | 2023-2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $126.64 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $126.14 | 2024-2025 | Tlando |
| Abbott Laboratories | $123.36 | 2021-2022 | |
| Antares Pharma, INC. | $122.04 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $117.15 | 2021-2025 | |
| Ibsa Pharma INC. | $106.81 | 2019-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $105.45 | 2019-2025 | |
| Zealand Pharma US, INC. | $84.54 | 2021-2022 | |
| Clarus Therapeutics INC. | $72.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.86 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $71.02 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $68.93 | 2024 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $64.06 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $62.19 | 2025 | Twiist |
| Avvisto Therapeutics, LLC | $61.65 | 2024-2025 | Cycloset |
| Ultragenyx Pharmaceutical INC. | $57.76 | 2021-2024 | Crysvita |
| Beta Bionics, INC. | $57.03 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vivus LLC | $48.85 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $48.61 | 2024-2025 | |
| Tolmar, INC. | $45.38 | 2025 | Jatenzo |
| Boston Scientific Corporation | $33.83 | 2024-2025 | Wavewriter Alpha Prime 16, Enhance Transcarotid Peripheral Access Kit |
| Genentech USA, INC. | $31.04 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $29.30 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.47 | 2019-2020 | |
| Gilead Sciences, INC. | $27.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.06 | 2019-2020 | |
| Kyowa Kirin, INC. | $26.38 | 2023 | Crysvita |
| Cequr Corporation | $25.33 | 2023-2024 | Cequr Simplicity |
| Therapeuticsmd, INC. | $24.29 | 2019 | |
| Bigfoot Biomedical INC | $21.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.28 | 2021 | |
| Amryt Pharma Holdings Ltd | $19.05 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.72 | 2022 | |
| Aytu Biopharma, INC. | $18.14 | 2020 | |
| Medtronic, INC. | $16.62 | 2023 | Minimed 780g |
| Vifor Pharma, INC. | $16.08 | 2020 | |
| Exeltis, USA INC. | $15.59 | 2023 | Slynd |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Althera Pharmaceuticals LLC | $11.83 | 2022 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$762.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Aronoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.